Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.51 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.48 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | EEF2K | O00418 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9556420 | 1.00 | FFAR1 (0.51) | FFAR1GABBR2GABBR1TSHRKMT2A | |
| SCHEMBL27862777 | 1.00 | FFAR1 (0.51) | FFAR1GABBR2GABBR1TSHRKMT2A | |
| SCHEMBL1754734 | 0.85 | TSHR (0.53) | TSHRKMT2ACYP2C19TRPA1 | |
| SCHEMBL434696 | 0.85 | ESR1 (0.58) | FFAR1KMT2ACYP2C19 | |
| SCHEMBL6798718 | 0.85 | CYP2C19 (0.47) | GABBR2GABBR1TSHRKMT2ACYP2C19 | |
| SCHEMBL31326025 | 0.85 | TSHR (0.53) | TSHRKMT2ACYP2C19TRPA1 | |
| SCHEMBL6063192 | 0.85 | CYP2C19 (0.47) | GABBR2GABBR1TSHRKMT2ACYP2C19 | |
| SCHEMBL3055864 | 0.85 | TSHR (0.44) | FFAR1GABBR2GABBR1TSHRKMT2A | |
| SCHEMBL11568787 | 0.85 | KMT2A (0.46) | FFAR1GABBR2GABBR1TSHRKMT2A | |
| SCHEMBL10260682 | 0.83 | FFAR1 (0.62) | FFAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117110481-A | Auxiliary determination method for unknown ketone-containing perfume in tobacco essence | 吉林烟草工业有限责任公司 | 2023-11-24 | — | — | CN | claimed |
| CN-117074574-A | Method for assisting in determining unknown aldehyde-containing perfume in tobacco essence | 吉林烟草工业有限责任公司 | 2023-11-17 | — | — | CN | claimed |
| CN-119776295-A | Olefin reductase, coding gene, vector, engineering bacteria and application thereof | 浙江工业大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-118530130-A | Preparation method of henibut | 杭州国瑞生物科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-117110481-A | Auxiliary determination method for unknown ketone-containing perfume in tobacco essence | 吉林烟草工业有限责任公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117088744-A | Method for constructing fluorine-containing compound by catalyzing decarboxylation of alkyl carboxylic acid by ketone compound | 中山大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-117074574-A | Method for assisting in determining unknown aldehyde-containing perfume in tobacco essence | 吉林烟草工业有限责任公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| EP-3676266-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | Ctxt Pty Ltd (AU) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| CN-107188808-A | A kind of synthetic method of the phenylbutyric acid hydrochloride of 4 amino 3 | 江苏斯威森生物医药工程研究中心有限公司 | 2017-09-22 | — | — | CN | disclosed |
| US-5366987-A | Enzyme inhibitors, anticholesterol | WARNER-LAMBERT COMPANY (US) | 1994-11-22 | — | — | US | disclosed |
| WO-1994019330-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0600950-A1 | AMIDE TETRAZOLE ACAT INHIBITORS. | WARNER LAMBERT CO (US) | 1994-06-15 | — | — | EP | disclosed |
| US-5242939-A | Hypotensive | WARNER-LAMBERT COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| WO-1993004052-A1 | AMIDE TETRAZOLE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1993-03-04 | — | — | WO | disclosed |
| EP-0219961-B1 | IRREVERSIBLE DOPAMINE-B-HYDROXYLASE INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-03-08 | — | — | EP | disclosed |
| US-4760089-A | Benzonitrile derivative; enzyme inhibitor | SMITHKLINE BECKMAN CORPORATION (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0219961-A1 | Irreversible dopamine-B-hydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1987-04-29 | — | — | EP | disclosed |
| US-4153713-A | NEUROPSYCHOTROPIC AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | KAT5, KAT6A, KAT2A | FFAR1 4034/4885GABBR2 3937/4885GABBR1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.